DarioHealth Corp. is a leading global digital health company serving its users with dynamic mobile health solutions. In today’s day in age, knowledge of health and treatment is being democratized and we believe people deserve to know everything about their own health, and at the same time have the best tools to manage their treatment.

Founded in 2011, DarioHealth employs a revolutionary approach whereby harnessing big data, we have developed unique ways for people to analyze and personalize their chronic disease management. DarioHealth’s approach has taken the best of both worlds – the world of the wearable market, which is projected to reach $51.6B in just a few years, and the monitoring market that is climbing toward the $30B mark – and flipped traditional health upside down. We are moving from periodic data to continuous data, from general treatment to personalized treatment, and from theory-driven solutions to adapted data & AI/ML technology. DarioHealth’s solutions span the full spectrum of disease monitoring, management, populations, and engagement.

What truly makes DarioHealth remarkable is the fact that it has steadily grown from being a user-centric, direct-to-consumer company to a mature organization that is fully data-driven and able to provide a wide-range of managed care solutions. At the hub of it all is DarioHealth’s proprietary engagement platform, which has been painstakingly built by carefully monitoring and analyzing big data. Today, DarioHealth boasts phenomenal solutions and automated, full-suite services for the biggest players in the diabetes care management space.

The company is led by visionary CEO and Chairman, Erez Raphael. After years in software development and senior management roles at some of Israel’s leading high-tech companies, Mr. Raphael had a close encounter with diabetes and decided to channel all of his energies into combatting this disease that affects a fast growing number of people each year. Under his leadership, the company was uplisted to the Nasdaq market under the ticker name DRIO.

The world leading Dario Blood Glucose Monitoring System has US FDA clearance and approval from the European CE, Health Canada, and Australia’s TGA. It is commercially available in the United States, Canada, the United Kingdom, Germany, Italy, the Netherlands, and Australia.

Our team

Erez Raphael

Chief Visionary & CEO/Chairman

Zvi Ben-David

CFO

Dror Bacher

COO

Olivier Jarry

Strategic Partnerships

Tracey Wielinski

Acting VP RA/QA/CL

João Mendes-Roter

VP Marketing

JC Muyl

Head of Commercialization - North America

Adiel Levin

Director, Global Partnerships & Commercialization

Yinon Amir

Head of Software Innovation

Dominique Wilkins

Legendary Customer

Alon Yefet

Customer Relations Manager

Eitan Feinger

Director, R&D

Shmuel Herschberg

Director, Marketing & User Engagement

Dov Oppenheim

Co-Founder & Production Chief

Nir Ziv

Director of Operations

Professor Itamar Raz

Medical Director

Eti Visbrot

Talent Manager

Yahel Nir

Director of Finance

Lyr Bar

Director of Quality

Ran Shochat

Software Development Director

Inbal Gross

Design Experience Manager

Sharon Elizur, RD, CDN, CDE

Complaint Coordinator

Yifat Hershcovitz, Ph.D

Scientific Manager

Janice Baker, RD, CDE, CNSC, BC-ADM

Scientific Advisory

Susan Sloane, RPh, CDE

Scientific Advisory

Evan Lang

Social Media Maestro

Sara Kahn, RN

Sales Team Leader

Board of Directors

Hila Karah

Professor Richard Stone

Dennis M. McGrath

Colonel (IDF res.) Yalon Farhi

Allen Kamer

Dr. Malcolm Hoenlein

Rami Yehudiha

Advisory Board

Robert G. Faissal

Erez Levy

Dr. Peter Kash